TSX closed
Loading markets…

Advertisement

Stocks

What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:EPRX.TO

Follow EPRX

Photos provided by Pexels

Eupraxia Pharmaceuticals Inc (EPRX.TO) has seen a modest increase in its stock price over the past week, reflecting recent market activity and company developments.

Eupraxia Pharmaceuticals Inc, a player in the health care sector, closed at C$9.09 on Wednesday, with a slight daily decline of 0.21%. However, the stock has appreciated by 2.52% over the past week. While no major news has emerged recently, the company's public offerings have caught the attention of investors.

Advertisement

Eupraxia Pharmaceuticals Inc

EPRX.TO

Full stock page →

EPRX.TO

Eupraxia Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↑ $1.31 (13.26%)
120 day period
$8.22$10.61$12.99Apr 13Jul 8Oct 1

Market cap

$858.29M

52W high

$13.08

52W low

$7.35

1W change

-2.70%

Beta

1.49

Analyst Price Targets

Based on analyst covering EPRX · as of Sep 28, 2026

📈

Wall Street analysts forecast EPRX stock price to rise 46.0% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$16.33

+46.0% Upside

Previously C$16.00 on Sep 17, 2026

Current Price

C$11.19

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on EPRX's historical volatility

HistoricalForecast68%95%
C$4.28C$11.78C$19.27C$26.76C$34.26C$41.75TodayMay 26Jul 29Oct 1Nov 13Dec 27Feb 8

30-Day Vol

92.7%

Annualized

90-Day Vol

68.3%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$13.38

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$11.88C$8.62 – C$16.36
60 trading daysC$12.60C$8.02 – C$19.82
90 trading daysC$13.38C$7.69 – C$23.29

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Eupraxia's recent public offerings and ongoing clinical trials may influence investor sentiment, despite the stock's overall decline this year. Investors should keep an eye on the company’s financial health and clinical progress as indicators of future performance.

C$9.09 closing price with a 1D change of -0.21%.

The stock has a 52-week range of C$6.94 to C$12.86, indicating potential volatility and room for growth.

Bull case

Eupraxia's recent public offerings have strengthened its financial position, providing capital for ongoing clinical trials. The company is showing promising results in its lead program, EP-104GI, which could give it a competitive edge in the market.

Bear case

Despite recent gains, Eupraxia's stock is still down 10.61% year-to-date, and the company continues to report negative earnings. The stock's high volatility, indicated by a beta of 1.50, may pose risks for investors.

Recent Price Action

Advertisement

Eupraxia Pharmaceuticals Inc (EPRX.TO) experienced a closing price of C$9.09 on Wednesday, marking a slight decline of 0.21% for the day. Over the past week, the stock has gained 2.52%, indicating a positive trend amidst a challenging year, with a year-to-date decrease of 10.61%. The stock's recent movements reflect investor sentiment and market conditions.

Company News and Catalysts

While no major news has been reported in the past week, Eupraxia has recently announced the pricing and completion of public offerings, raising significant capital. On February 19, 2026, the company priced a public offering aiming to raise US$55 million, followed by the successful closure of a US$63.2 million offering on February 20, 2026. These developments may provide the necessary funds for ongoing clinical trials and operational expenses, which investors are closely watching.

Technical Picture

The technical outlook for Eupraxia Pharmaceuticals shows a last close of C$9.09, slightly above its 50-day moving average of C$9.03, which is up 0.6%. However, it remains below the 200-day moving average of C$9.76, indicating a longer-term downtrend. The stock is currently trading within a 52-week range of C$6.94 to C$12.86, suggesting significant potential for volatility. The recent trading volume of 69,212 shares is below the 20-day average of 57,778 shares, indicating lower trading activity.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 12, 2026
Last Updated: September 22, 2026

Core portfolio

Awesome Portfolio™

15.1% a year since 2017, against 9.9% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+15.1%

Awesome Portfolio™

+9.9%

S&P/TSX

+5.2 pp better a year

Total return

+260%

Awesome Portfolio™

+137%

S&P/TSX

+123 pp better than the TSX

2017-07-31 to 2026-09-17, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-17
-11.7%42.8%97.2%151.6%206.0%260.4%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement